2023
High-Level Drug-Resistant Mutations among HIV-1 Subtype A6 and CRF02_AG in Kazakhstan
Sanaubarova A, Pujol-Hodge E, Dzissyuk N, Lemey P, Vermund S, Brown A, Ali S. High-Level Drug-Resistant Mutations among HIV-1 Subtype A6 and CRF02_AG in Kazakhstan. Viruses 2023, 15: 1407. PMID: 37515095, PMCID: PMC10384832, DOI: 10.3390/v15071407.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug Resistance, ViralGenotypeHIV InfectionsHIV-1HumansKazakhstanMutationPhylogenyConceptsAntiretroviral therapySubtype A6Drug-resistant mutationsDrug resistanceEffective antiretroviral therapySuppressive antiretroviral therapyAntiretroviral drug resistanceDrug resistance monitoringHigh-level drug resistanceDrug regimensHIV incidenceHIV epidemicHIV-1Sustained transmissionMolecular epidemiologySubtypesPLHIVHIVG190SDifferent mutational pathwaysMutationsK101ED67NHigh levelsA62V
2022
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan
Mukhatayeva A, Mustafa A, Dzissyuk N, Issanov A, Mukhatayev Z, Bayserkin B, Vermund SH, Ali S. Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan. Scientific Reports 2022, 12: 17195. PMID: 36229577, PMCID: PMC9562405, DOI: 10.1038/s41598-022-22163-7.Peer-Reviewed Original Research
2021
Hepatitis B, Hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan
Mukhatayeva A, Mustafa A, Dzissyuk N, Issanov A, Bayserkin B, Vermund SH, Ali S. Hepatitis B, Hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan. Scientific Reports 2021, 11: 13542. PMID: 34188081, PMCID: PMC8241865, DOI: 10.1038/s41598-021-92688-w.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoinfectionFemaleHepatitis BHepatitis C, ChronicHIV InfectionsHumansKazakhstanMaleTuberculosisConceptsStudy participantsHepatitis CHepatitis BRegular screeningHIV-positive study participantsHCV/HBVHIV-positive patientsTB/HIVHIV/HCVDirect acting antiviralsHIV/tuberculosisOpiate substitution therapyInjection drug useHarm reduction effortsAvailability of ARTHCV infectionTB infectionActing antiviralsCertain age groupsPositive patientsHIV infectionHIV prevalenceSubstitution therapyVaccination protocolsQuadruple infections